Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a milk protein help dialysis patients fight anemia?

NCT ID NCT07706582

Disease control Sponsor: Beni-Suef University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 15, 2026 · Last updated Jul 21, 2026 · Updated 3 times

Summary

This study tests whether oral lactoferrin, a protein found in milk, can improve anemia and bone health in adults with end-stage kidney disease on dialysis. Participants receive either lactoferrin, IV iron, or both for three months, alongside their usual anemia medication. The goal is to see if lactoferrin can raise hemoglobin levels and improve markers of bone health.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
oral lactoferrin, a dietary supplement, and IV iron dextran
What this could lead to
If effective, lactoferrin could offer a gentler, oral option to manage anemia and bone health in dialysis patients.
What could go wrong
This is a small, early-phase trial, so results may not be conclusive. Lactoferrin may not work as well as standard IV iron.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

108 people

The number who actually took part.

Started

Nov 2025

Expected to finish

Jan 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 85 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adult patients aged over 18 * Diagnosed with chronic kidney disease (CKD) on maintenance hemodialysis (3 sessions/week). * Diagnosed with functional iron deficiency anemia Exclusion Criteria: * Active infection * Inflammation (any cause other than CKD) * Recent bleeding and recent blood transfusion * Patients with decompensated medical conditions

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ESRD (end-stage renal disease) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic renal failure syndrome end stage renal failure iron deficiency anemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ESRD (end-stage renal disease) Iron deficiency anemia (IDA)

Contacts and locations

Locations

  • Theodor Bilharz Research Institute (TBRI)

    Giza, El-Nile Street, Imbaba, Warrak El Hader, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.